Recent studies are reviewed indicating that the transcription factor early growth response-1 (Egr1) is a direct regulator of multiple tumor suppressors including TGFb1, PTEN, p53, and fibronectin. The downstream pathways of these factors display multiple nodes of interaction with each other, suggesting the existence of a functional network of suppressor factors that serve to maintain normal growth regulation and resist the emergence of transformed variants. Paradoxically, Egr1 is oncogenic in prostate cancer. In the majority of these cancers, PTEN or p53 is inactive. It is suggested that these defects in the suppressor network allow for the unopposed induction of TGFb1 and fibronectin, which favor transformation and survival of prostate tumor epithelial cells, and explain the role of Egr1 in prostate cancer. Egr1 is a novel and logical target for intervention by gene therapy methods, and targeting methods are discussed.
Introduction
Egr1 or the early growth response gene product is a zincfinger transcription factor of 59 000 Da that, unusually, appears to activate transcription by binding to DNA as a monomer. The role of Egr1 in cancer was last reviewed in these pages in 1998. 1 The thrust of the review was the emerging evidence indicating that Egr1 has significant tumor suppressor properties. Two mechanisms -the direct induction of the epithelial cell suppressor TGFb1 and the direct induction of p53 in melanoma cells to promote apoptosis -were emphasized. Numerous other genes implicated in the regulation of cancer such as members of the PDGF and IGF families have promoter elements consistent with regulation by Egr1, and the evidence that Egr1 functionally regulates these genes was summarized. Since then, a wealth of new information has extended our mechanistic knowledge of the suppressor theory, especially for the role of the TGFb1, IGF-II, PTEN, fibronectin, p53, and p73 genes, and has added the complication that Egr1 plays an important role in the progression of prostate cancer. These topics are briefly reviewed and we offer the hypothesis that Egr1 participates in the regulation of a network of suppressor gene products. In the case of prostate cancer, however, specific defects in this network may lead to the unopposed action of Egr1 on TGFb1 that favors tumor progression.
TGFb1
Strong evidence indicates that under physiological conditions TGFb1 is growth inhibitory for cells of epithelial origin that bear an intact TGFb1 RII receptor signal transduction pathway. 2, 3 The promoter of the human TGFb1 gene contains at least two Egr1-binding sites, both of which can bind Egr1, leading to the activation of transcription. 4, 5 The significance of this interaction in human tumor cells was shown by re-expression of Egr1 in human HT1080 fibrosarcoma cells, which do not normally express Egr1 but do exhibit functional TGFb1 RII receptors.
5 HT1080 cells that have been made to express Egr1 acquire the ability to synthesize and secrete precursor TGFb1 that becomes activated and acts in an autocrine fashion to suppress growth. Chromatin immunoprecipitation of Egr1-DNA complexes has confirmed the regulation of TGFb1 by Egr1 in living cells. 6 Thus, Egr1-induced TGFb1 is a growth suppressor in HT1080 cells in spite of the apparent mesenchymal origin of these cells. A number of additional studies have documented functional TGFb1 expression in correlation with or following expression of Egr1 in other cells types as well as in vivo (Table 1 ). In addition to HT1080 cells, this suppression mechanism has been observed in human glioblastoma cells 7 and in the mouse. 8 In connective tissue cells, TGFb1-induced fibrosis in a variety of settings may also be attributed to Egr1. [9] [10] [11] Thus, TGFb1 appears to be a general effector of Egr1-dependent growth regulation.
Fibronectin and plasminogen activator inhibitor-1 (PAI-I)
Potential targets of the TGFb1/Smad signal transduction pathway that may explain the transformation-suppressor activity of TGFb1 include fibronectin and PAI-1. 2, 12 This possibility was examined in several human glioblastoma cells. Established human cell lines 13 and surgical specimens of glioblastoma 14 or primary cultures of the tumors 15 commonly exhibit low or undetectable levels of Egr1 consistent with a role of Egr1 in the cause or development of glioblastoma. 13, 14 Re-expression of Egr1 in several human glioblastoma cell lines such as U251 led to increased expression of TGFb1, fibronectin, and PAI-1. 13 Surprisingly, direct addition of activated TGFb1 to the cells induced expression of PAI-1 but not fibronectin. This led to the discovery that fibronectin is a direct target gene of Egr1 via two closely spaced Egr1-binding sequences in the proximal promoter. 13 Both fibronectin and PAI-1 induced by Egr1/TGFb1 are secreted and become part of the extracellular matrix where they greatly increase attachment, an effect that is blocked by addition of RGD-containing peptides or neutralizing antibodies. The 17 Indeed, Egr1 stimulates coordinated expression of TGFb1, fibronectin, and PAI-1. All the three have been found to participate in the restoration of a normal phenotype in HT1080 cells. 7 Comparable examples have been observed by others ( Table 1) , indicating that this mechanism may be general.
Fibronectin and PAI-1 are known to contribute to anchorage-dependent growth control. 18, 19 One mechanism involves the interaction of fibronectin with specific integrins, leading to activation of the protein kinase-B/ Akt (PKB/AkT) pathway 19 ( Figure 1 ). This pathway is a major site of action of the tumor suppressor PTEN, thereby suggesting a potential crosstalk downstream of fibronectin, as described below.
PTEN
The tumor suppressor gene, PTEN/MMAC1/TEP1, is a proapoptotic factor that is frequently suppressed or mutated in a variety of human cancers (reviewed in Virolle et al. 20 ). Egr1 is one of the first transcription factors shown to directly regulate the expression of PTEN and the first shown to regulate PTEN in living cells. 20 The proximal promoter of PTEN is GC rich and contains one functional Egr1-binding site. We have examined the regulation of PTEN in a variety of human cell types and in the Egr1-null mouse system (Table 1 ). In 293T human fetal kidney cells, Egr1 activates a PTEN-promoter-driven luciferase reporter system, which is inhibited by low concentrations of Egr1 antisense oligonucleotides. EMSA, mutation analysis of DNA-binding sequence, and chromatin immunoprecipitation of Egr1-PTEN promoter complexes from living cells have been used to test the functional role of this site. These results indicate that Egr1 is a direct and functional regulator of the PTEN gene.
Irradiation of wild-type mice strongly induces Egr1 and PTEN mRNA; however, PTEN expression is not induced in irradiated Egr1-null mice, indicating that Egr1 regulates the expression of PTEN in the whole animal. 20 The functional significance of PTEN regulation by Egr1 is suggested further by the observation that MEFs from Egr1-null mice are resistant to apoptosis following UV irradiation, whereas MEFs from wild-type littermates rapidly undergo apoptosis following UV irradiation. The apoptosis response could be rescued by exogenous expression of Egr1 in MEFs from the Egr1-null mice. These observations provide an additional mechanism for the tumor suppressor activity of Egr1.
In addition to the mouse system and human cells (MEFs, HT1080, 293T 20 ), consistent significant effects have been observed in other cells and tissues, [21] [22] [23] [24] [25] ( Table 1) . Moorehead et al. 22 observed that Egr1 is induced by and required for IGF-II-dependent induction of PTEN in the mouse mammary gland, an effect that is absent in Egr1-null mice. Human squamous carcinoma cells, SCCTF, can be stimulated to apoptosis by treatment with calyculin A, a potent inducer of apoptosis in several cell lines. 25 Treatment of these cells with Calyculin A causes elevation of Egr1 expression as well as its phosphorylation, which is known to increase its transactivation potential. 26, 27 This coincides with an elevation of PTEN expression. 25 RNA interference specific for the Egr1 gene inhibited not only Egr1 expression but also PTEN expression in these cells. These observations also support the view that Egr1 regulates PTEN expression during the initial steps of the apoptotic pathway. Silencing of Egr1 gene expression has also been revealing in the case of rat follicular thyroid cell transformation. 24 RT-PCR experiments performed on human thyroid tumors showed that the absence of Egr1 mRNA is always paralleled by the absence of PTEN mRNA, suggesting that Egr1-dependent mechanisms may play a role in the absence of PTEN gene expression that occurs during thyroid cell transformation.
24
Egr1 protein levels are suppressed or absent in a variety of human tumor cell lines 13, 28 and tumors, including breast carcinoma, 28 glioblastoma, 14,15 lung cancer, 29, 30 and lymphoma. 31 Moreover, in the case of human nonsmall-cell lung cancer, Ferraro et al. 32 examined an extensive series of samples from over 125 patients and observed that Egr1 expression predicts both PTEN level and survival to a high degree of significance. Low levels of Egr1 expression are associated with poor outcome and may have tumors resistant to therapy secondary to loss of 
p53Family: p53
Egr1 directly induces the transcription of p53 and may also bind with p53 in a cytoplasmic complex, although the significance of this interaction is not clear. 33 The stability of p53 is under extensive and complex regulation largely owing to intricate cytoplasmic and nuclear interactions, especially with Mdm2 and p14 ARF family members and related proteins (Figure 2 ) (reviewed in Nair et al. 34 and Liu et al.
35
). Thus, significant regulation of p53 expression by the direct induction of transcription may be unusual. Direct binding of the p53 promoter by Egr1 was first shown in human melanoma A375-C6 cells during thapsigargin-induced apoptosis. 34 Studies of the Egr1-null mouse system have revealed that Egr1 normally controls p53 expression leading to cell cycle arrest, senescence, and -for cells that survive 'crisis' -transformation. Freshly prepared primary fibroblasts (MEFs) from Egr1-null embryos exhibit a surprising phenotype characterized by rapid and apparent immortal growth, with no hint of replication-dependent growth arrest characteristic of MEFs from wild-type mice. 35 These cells express little or no p53 although the gene is intact. Thus, the Egr1-null cells were found to be insensitive to genotoxic stress and did not arrest following DNA damage as wild-type MEFs do. The properties of replicative senescence and DNA damage-induced growth arrest can be rescued by infection of the Egr1-null MEFs with a retrovirus expressing either p53 or Egr1. However, the Egr1-expressing retrovirus is ineffective at restoring replicative senescence or the DNA damage response in p53-null MEFs, indicating that Egr1 acts upstream of p53. Expression of Egr1 in Egr1-null MEFs is indeed accompanied by increased p53 protein. These studies indicate that Egr1 is a key regulator of p53. Lack of Egr1 in MEFs leads to suppression of key p53-dependent growth regulation mechanisms, including replicative senescence and DNA damage-induced growth arrest. Thus, regulation of p53 expression by Egr1 plays a central functional role in p53-dependent growth control in the mouse. 36 Consistent results have been observed in a variety of human cell and tissue systems (Table 1) . For example, p53 is mutated in the majority of fresh human glioblastoma and these tumors exhibit near normal levels of Egr1. 14 Conversely, in the minority of cases with wild-type p53, Egr1 mRNA and protein is significantly suppressed or absent, 14 suggesting that progression of human glioblastoma is associated with selection for either silencing Egr1 expression or inactivating mutations of p53, but not both.
The mechanistic basis for these findings has recently been suggested by Krones-Herzig et al. 37 The mouse and human promoters of p53 both contain at least two sequences consistent with Egr1-binding sites. In the case of the mouse, two sites have been shown to bind nuclear extracts of wild-type Egr1 cells but not from extracts of Egr1-null MEFs. Antibody and oligonucleotide studies confirm the specificity of binding of these sites by Egr1. Moreover, chromatin immunoprecipitation of Egr1-DNA complexes from living wild-type but not null MEFs and human tumor cells treated with Egr1 inducers but not from untreated cells have been isolated, indicating that Egr1 is an in vivo regulator of p53 in the mouse and human. Expression analysis of the wild-type MEFs reveals significantly increased transcript levels of p53 and nine known target genes of p53 compared to Egr1-null cells. Many additional transcript increases and decreases were also observed, of which 143 were known genes with the same significance level as the p53-regulated target genes. Using a bioinformatics approach, it was found that 66 of these occur in the reported literature in correlation with changes in Egr1. Program-assisted pathway construction showed that all of these informative observations could be accommodated on a single regulatory pathway consisting of only four branch points. In addition to p53, TGFb1, IGF-1, and IL-6 form branch points leading to up-or downregulation of all informative significant transcript changes of the expression analysis. The experimental observations of the direct regulation of p53 in MEFs by Egr1, together with the consistency of the expression analysis in the available literature, supports the concept that Egr1 is a functional regulator of p53 and p53-regulated genes in mouse MEFs.
p53 Family: p73 and p63
Several of the Egr1-dependent properties of p53 are reflected in the functions of p73, a member of the p53 family that undergoes multiple splicing effects, producing multiple isoforms. The regulation of p73 at the transcriptional level is controlled by two promoters that produce two main forms; one is named TAp73 because it contains the transactivating domain (TA) that gives it activities similar to those of p53. The other promoter regulates the expression of a set of isoforms known as DNp73, which Figure 2 Interactions between the two known Egr1 target genes, PTEN and p53. p53 controls the expression of PTEN and Mdm2, which in turns binds to and limits the amount of active p53. p53 controls the expression of the cell cycle inhibitor p21, which also is regulated by Egr1 through direct induction of TGFb1. Thus, Egr1, TGFb1, and p21 work to suppress cell cycling while the Egr1/PTEN path limits the role of p53.
Egr1 is
lacks the same transactivating domain and therefore generates effects distinct from those of p53. In fact, many of the roles of DNp73 are oncogenic, and are possibly related to a distinct set of target genes that can be transcriptionally regulated. 38 Ding et al. 39 noticed that there were putative Egr1-binding sites in the p73 promoter and later it was shown that Egr1 can upregulate the p73 gene to induce the apoptosis of neuroblastoma cells. 40 Kartasheva et al. 41 noted that DNp73 can also regulate the expression of a variety of genes independently of p53, and that Egr1 is an important player in this effect. Our recent results in this regard (unpublished data of Jianxiu Yu and ED Adamson) indicate that a complicated set of feedback loops come into play between the p53 and p73 promoters and Egr1, further underlying the importance of a network of stress response genes that induce growth arrest, stress response, and apoptosis. The p63 family of gene products that are related to p53 may also play a role but they appear not to be regulated by Egr1. The p63 and p73 genes are infrequently mutated in cancers and this is also true for Egr1. Therefore, TAp73 and TAp63 could act in place of p53 in p53-null cancer cells when an apoptosis response is required to remove damaged cells.
Egr1 is a suppressor in vivo
Egr1-null mice are prone to induction of skin tumors. 37 In these studies, wild-type and Egr1-null mice were challenged with the two-step skin carcinogenesis model by treatment of the skin with the mutagen DMBA (7,12-dimethylbenzanthracene), followed by treatment with the tumor promoter tetraphorbol acetic acid. Wild-type mice developed tumors, on average, 11 weeks after induction, whereas mice treated with either agent alone or vehicle whether wild type, null, or heterozygous for the Egr1 gene did not develop tumors. In contrast, Egr1-null mice exposed to the complete protocol uniformly developed tumors with an average time of appearance of 6 weeks -a significant difference and a time when no tumors were apparent in the wild-type control mice. 37 The suppressor network concept
PTEN-Mdm2 interactions
A major regulator of cellular levels of active p53 is the formation of p53-protein complexes in the nucleus involving the mouse double minute2 gene product (Mdm2) or the human homolog, the p53-binding protein.
Mdm2 is an oncoprotein that leads to sequestration of active p53 and also, owing to the ligase activity of Mdm2, ubiquitination and proteosomal degradation, thereby further limiting the amount of active p53 (reviewed in Kartasheva et al. 41 and Mayo and Donner 42 ) (Figure 2 ). Recent observations show that phosphoinositide 3-kinase (PtdIns 3-kinase, PI3K)-Akt signaling promotes the phosphorylation and translocation of the Mdm2 oncoprotein into the nucleus, thus facilitating the downregulation of p53. 42, 43 Donner and co-workers observed that PTEN inhibits activation of Akt by dephosphorylation of the PtdIns 3-kinase activator phospho-inositol triphosphate (PIP3), hence restricting Mdm2 to the cytoplasm in human U87 glioblastoma cells. 42, 43 Restriction of Mdm2 to the cytoplasm preserves p53 function and promotes growth arrest and apoptosis of the cancer cells following DNA-damaging chemotherapy. It has been suggested that there is a direct connection between these two major tumor suppressors that act together to respond to stresses and transformation. Moreover, as shown here, both p53 and PTEN are direct targets of the Egr1 transcription factor in a variety of cell types.
p53-PTEN interactions
Another example of network effects is illustrated by the observation that p53 itself is a strong transactivator of the PTEN promoter. 44 This induction is augmented by Egr1 (unpublished data of I de Belle and ED Adamson). Thus, the crosstalk between PTEN and p53 is expected to be favored by an increase in Egr1 and disrupted by suppression of Egr1 -a common circumstance in many human cancers. The possibility that Egr1 deficiency has effects in vivo has been shown by the analysis of Egr1-null mice. In Egr1-null mice, the level of PTEN expression is reduced in all tissues except the thymus and is uninducible even in the thymus. 20 This observation provides strong support for the thesis that deficiencies of Egr1 expression in vivo may have consequences on the tumor suppressor function of PTEN in vivo.
PTEN and TGFb1/fibronectin compete for regulation of apoptosis At least two additional Egr1 target genes, fibronectin and TGFb1, display downstream signaling activities that potentially interact with the p53-PTEN network. Fibronectin, by virtue of its binding and activation of specific integrins such as b1 is a major mediator of cell attachment, activation of focal adhesion kinase (FAK), and cell survival. 18 Integrin binding leads to activation of the antiapoptotic pathway Akt via activation of FAK. 18 As described earlier, expression of Egr1 in HT1080 human fibrosarcoma cells results in increased secretion of functional fibronectin 7, 13 and activation of FAK. 45 Activated Akt is a major modulator of apoptosis at several levels (reviewed in Ruoslahti 18 and Kishimoto et al. 47 ) (Figure 1 ). It phosphorylates and inactivates the proapoptotic factors BAD and Caspase 8. Akt prevents the release of cytochrome c from mitochondria and inactivates the forkhead transcription factors (FKLR), which are known for their proapoptotic effects. Moreover, Akt mediates integrin-induced activation of the antiapoptotic factor Bcl-2. Thus, activation of Akt constitutes an important cell survival mechanism. Concomitantly, the activity of Akt is opposed by the action of PTEN. These influences establish a critical balance (Figure 1 ). In the absence of PTEN, any alteration that gives rise to autonomous activation of the integrin/FAK/Akt pathway Egr1 is a potential target for gene therapy of prostate cancer V Baron et al may favor the survival of unattached cells. In the presence of PTEN, the Akt survival pathway is opposed by the PTEN-catalyzed hydrolysis of PIP3, thereby increasing apoptosis of unattached cells, a phenomenon termed 'anoikis' (Gr., oikos, home; anoikos, homelessness) by Ruoslahti 18 and Frisch and Screaton. 46 This mechanism protects normal cells from the emergence of anchorageindependent populations. Cells that gain autonomous Akt activity, such as occurs upon LOH, or complete deletion or inactivating mutations of PTEN, may escape this mechanism. Indeed, genetically altered mice that are heterozygous for inactivating mutations of PTEN exhibit constitutively elevated Akt activity in a variety of tumors including the thyroid, endometrium, breast, and prostate carcinomas as well as T-cell lymphomas. 47 We propose that Egr1, by inducing the expression of functional PTEN as well as functional fibronectin and other attachment factors such as PAI-1, contributes to the maintenance of the critical balance of survival vs apoptosis determined by Akt activity (Figure 1 ).
TGFb1 interacts at several levels
The TGFb1 signaling pathway also interacts with the network. First, as noted, TGFb1-induced PAI-1 is secreted and functions to facilitate cell attachment. 13 Second, several growth inhibitors such as p27 and p21
Cip1/Waf151-53 are regulated by the TGFb1 signal transduction pathway. p21
Waf1 is also under the direct regulation of p53, indicating a potential cooperation between Egr1-induced p53 and Egr1-induced TGFb1 in controlling cell growth. In certain cell types such as HT1080, 54 fibronectin is known to be a direct target gene of the TGFb1 signal transduction pathway, thereby cooperating with Egr1-induced fibronectin. Thus, Egr1-induced TGFb1 may lead to several cooperative interactions with tumor suppressor networks (Figure 1 ).
In summary, recent studies indicate that Egr1 is a direct regulator of at least four major suppressors: TGFb1, PTEN, p53 family members, and fibronectin. These factors have several overlapping functions, suggesting that cooperative interactions occur that favor the maintenance of the normal cell phenotype and work to eliminate the emergence of transformed cells. The combined direct regulatory effects of Egr1 and the potential downstream effects are summarized in Figure 3 .
Egr1-induced oncogenesis of prostate cancer
Consistent with a role as a tumor suppressor, deletion of the Egr1-containing 5q31 region has been associated with other malignant conditions such as lymphoma of Bloom's Syndrome 31 and small cell lung carcinoma (SCLC). 29 Decreased or absent Egr1 protein expression occurs in NSCLC 30 and glioblastoma. 14 The observations indicate that Egr1 expression is commonly suppressed in tumors as has been observed in cells lines. 13, 28 Paradoxically, increased expression of Egr1 is consistently observed in prostate cancer where growing evidence indicates that Egr1 is oncogenic. Russell and co-workers 55 observed that Egr1 mRNA levels were elevated in 12 of 12 cases of organ-confined prostate cancer but not in breast or ovarian cancers, or in rapidly dividing rat ventral prostate cells. Egr1 mRNA was detected in epithelial and stromal cells at tumor margins but not in lymph node metastases. The correlation was extended to protein expression. In addition, Egr1 expression was significantly increased in tumors with Gleason scores of 8-10. 56 The protein NAB2 (NGF-1A-binding protein), which represses the transcriptional activity of Egr1, is downregulated in primary prostate carcinomas. 57 Thus, both upregulation of Egr1 and loss of its repressor NAB2 may contribute to increased levels of Egr1 activity in human prostate cancer. The functional effects were demonstrated by Milbrandt and co-workers who examined the TRAMP mouse model of prostate cancer following the crossing of these mice with Egr1-null mice. 58 TRAMP mice spontaneously develop prostate cancer owing to the expression of the SV40 T-antigen under the control of a prostatespecific probasin promoter. Owing to SV40 T-antigen expression, it is likely that p53 is inactivated. Tumor initiation and tumor growth rate were not affected by the lack of Egr1; however, Egr1 deficiency significantly delayed the progression from prostatic intraepithelial neoplasia to invasive carcinoma. Further evidence for a role of Egr1 in oncogenesis was provided by experiments using specific high-affinity Egr1 antisense oligonucleotides. [59] [60] [61] It was shown that in a series of mouse and human prostate cancer cells, Egr1 antisense inhibited cell proliferation, colony formation, and growth in soft agar, 63 Interestingly, several genes identified in this screen are associated with neuroendocrine differentiation, which is known to occur frequently in murine prostate cancer. Another Affymetrix microarray analysis compared mouse prostate cancer cells TRAMP-C2 in the presence or absence of Egr1 antisense. 64 A total of 960 genes were regulated by endogenous Egr1 and several new targets were identified. Some of these play important roles in cell proliferation or apoptosis, such as cyclin D2, p19INK, Fas, and TGFb1. Direct regulation of the expression of these genes was confirmed by quantitative PCR, Western analysis, and chromatin immunoprecipitation.
The network concept of tumor suppressors provides additional suggestions for the basis of the oncogenic properties of Egr1 in prostate cancer. For example, in the case of prostate cancer, PTEN is the most commonly altered gene known. The region on chromosome 10q that harbors the PTEN gene is hemizygously deleted in many human cancers, with a frequency reaching 60-80% in the case of prostate cancer. [65] [66] [67] Interestingly, even in prostate cancer cells that display PTEN normally, Egr1 was unable to regulate PTEN expression 61 (as in unpublished results). This may be because of hypermethylation of PTEN promoter, which prevents Egr1 from binding (our unpublished results). PTEN hypermethylation occurs in about 50% of prostate cancer cases. 68 Thus, in prostate tumors where PTEN is not mutated or deleted, hypermethylation of its promoter may preclude regulation by Egr1. In addition, p53 is inactivated in up to 25-50% of prostate cancer cases. 69 Therefore, PTEN and/or p53 are inactivated in the majority of prostate cancers. In these cases, Egr1 may have an unopposed effect on Akt activation by continued induction of fibronectin. Fibronectin has long been associated with the stimulation of anchorage-independent growth. 70 The expression of fibronectin correlates with features of aggression such as metastases in prostate cancer 71, 72 and is a known activator of the Akt pathway in prostate cancer cells. [73] [74] [75] An important feature of the suppressor network in prostate tumors is Egr1-induced TGFb1. 61, 63, 64 TGFb1 has diverse roles and may have the net effect of promoting the progression of prostate cancer (reviewed in Albrecht et al. 72 and Zheng et al.
73
). TGFb1 may also facilitate detachment and metastasis. 76 An additional important mechanism of tumor growth promotion by TGFb1 may be via autocrine stimulation of endothelin-1, implicated in prostate tumor progression. 77 Thus, it may be speculated that in the absence of PTEN and/or p53, Egr1 becomes an oncogenic agent in prostate cancer via the effects of its target genes, fibronectin and TGFb1. Furthermore, the oncogenic effect of TGFb is not restricted to prostate cancer. Recently, the progression and metastases of breast cancer in the transgenic mouse was shown to be driven by autocrine TGFb1 secretion, especially during the stage when epithelial breast cells are transforming into mesenchymal cell types. 78 While it is of interest that the tumor suppressor network can both accommodate growth suppression and the oncogenic role of Egr1, this hypothetical basis for an oncogenic role of Egr1 remains untested. The preponderance of experimental evidence, however, strongly indicates that in formed prostate carcinomas, Egr1 is oncogenic. We suggest that Egr1 is a valid target for suppression in prostate cancer by gene therapy methods.
Targeting Egr1 for gene therapy of prostate cancer
How can one exploit the indications that Egr1 promotes prostate cancer for therapy in view of the arguments that Egr1 is a suppressor factor in normal tissue via regulation of a network of well-known suppressor factors? Two approaches are apparent. First, in the whole animal, temporary suppression of Egr1 in nonprostatic tissue may not be disastrous. For example, Egr1-null mice -unlike PTEN-and p53-null mice -do not experience an increased incidence of tumors. This may be related to the fact that other Egr1 family members compensate for the absence of Egr1. [79] [80] [81] For example, Egr4 can compensate for the deficiency of Egr1, which causes failure of LH receptor expression and sterility owing to failure of luteinizing hormone regulation and Leydig cell steroidogenesis. If this compensatory mechanism functions 'acutely', systemic agents that inhibit the expression of Egr1 may be appropriate at least for the relatively short term that therapy would be applied. Effective highaffinity antisense agents that block Egr1 expression in the mouse are known. 61, 62 Second, localized irradiation therapy may be combined with radiosensitive vectors that express proapoptic agents or Egr1 antisense or iRNA. Intriguingly, this approach may best utilize the Egr1 promoter itself. In a series of studies, Weischselbaum and co-workers have exploited the multiple CG-rich so-called CarG-boxes of the Egr1 promoter to prepare a variety of expression vectors that are induced by irradiation. [82] [83] [84] For example, the radioinducible DNA sequences from the CarG elements of the Egr1 promoter have been cloned upstream of a cDNA encoding TNFa and expressed as an adenoviral construct. Thus, expression of either an anti-Egr1 factor or a general Egr1 is a potential target for gene therapy of prostate cancer V Baron et al proapoptotic factor may be localized by combination with localized (or target directed?) radiotherapy. Moreover, expression by the Ad.Egr-TNF construct may be induced by a variety of clinically important chemotherapeutic agents such as cisplatin and doxorubicin. Resistance of PC-3 human prostate carcinoma to doxorubicin in vivo was reversed by combining doxorubicin with Ad.Egr-TNF and resulted in significant antitumor effects. 83 These approaches suggest that Egr1 is a theoretical and practical target for gene therapy of prostate cancer.
